DOCK2 and posterior cortical atrophy: In line with this, combining our markers into one variable (detectable methylated ctDNA by any assay vs. no detectable methylated ctDNA), increased the sensitivity for DOCK2 and HAPLN3 for both mCRPC progression and PCa-specific survival in de novo mPCa patients.